<Suppliers Price>

Varenicline Tartrate

Names

[ CAS No. ]:
375815-87-5

[ Name ]:
Varenicline Tartrate

[Synonym ]:
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine tartrate Champix
(2R,3R)-3-carboxy-2,3-dihydroxypropanoate de (1R,12S)-5,8-diaza-14-azoniatétracyclo[10.3.1.0.0]hexadéca-2(11),3,5,7,9-pentaène
Chantix
(1R,12S)-5,8-Diaza-14-azoniatetracyclo[10.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene (2R,3R)-3-carboxy-2,3-dihydroxypropanoate
(1R,12S)-5,8-Diaza-14-azoniatetracyclo[10.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaen-(2R,3R)-3-carboxy-2,3-dihydroxypropanoat
Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-, compd. with (6R,10S)-7,8,9,10-tetrahydro-6,10-methano-6H-azepino[4,5-g]quinoxaline (1:1)
Champix
Varenicline tartrate

Biological Activity

[Description]:

Varenicline Tartrate(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.IC50 value:Target: α4β2 nAChRVarenicline(CP 526555; Champix; Chantix) is a prescription medication used to treat smoking addiction. As a partial agonist it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Through these mechanisms Varenicline(CP 526555; Champix; Chantix) can assist some patients to quit smoking.

[Related Catalog]:

Signaling Pathways >> Membrane Transporter/Ion Channel >> nAChR
Signaling Pathways >> Neuronal Signaling >> nAChR
Research Areas >> Neurological Disease
Natural Products >> Others

[References]

[1]. Krebs P, Sherman SE. Review: Varenicline for tobacco cessation does not increase CV serious adverse events. Ann Intern Med. 2012 Aug 21;157(4):JC2-2.

[2]. Kikkawa, H.; Maruyama, N.; Fujimoto, Y.; Hasunuma, T. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. Journal of Clinical Pharmacology (2011), 51(4), 527-537.

[3]. Pachas GN, Cather C, Pratt SA et al. Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. J Dual Diagn. 2012;8(2):117-125.

[4]. Bordia T, Hrachova M, Chin M et al. Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum. J Pharmacol Exp Ther. 2012 Aug;342(2):327-34.

[5]. Varenicline


[Related Small Molecules]

PNU 282987 | Carbachol | GTS-21 | Methyllycaconitine citrate | Monepantel | Hexamethonium bromide | PNU-120596 | Centrophenoxine hydrochloride | ZSET1446 | Aniracetam | Desformylflustrabromine hydrochloride | EVP-6124 (hydrochloride) | α-Lobeline Hydrochcloride | ABT 594 hydrochloride | Varenicline

Chemical & Physical Properties

[ Boiling Point ]:
400.6ºC at 760 mmHg

[ Melting Point ]:
206-208ºC

[ Molecular Formula ]:
C17H19N3O6

[ Molecular Weight ]:
361.35

[ PSA ]:
23.79000

[ LogP ]:
4.49528

[ Storage condition ]:
Desiccate at RT

[ Water Solubility ]:
DMSO: >5mg/mL

MSDS

Safety Information

[ Symbol ]:

GHS02, GHS06, GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H225-H301 + H311 + H331-H370

[ Precautionary Statements ]:
P210-P260-P280-P301 + P310-P311

[ Hazard Codes ]:
Xn,N,T,F

[ Risk Phrases ]:
22-50-39/23/24/25-23/24/25-11

[ Safety Phrases ]:
22-57-45-36/37-16-7

[ RIDADR ]:
UN 3077 9 / PGIII

Synthetic Route

Precursor & DownStream

Precursor

DownStream

Articles

Concurrent access to nicotine and sucrose in rats.

Psychopharmacol. Ser. 232(8) , 1451-60, (2015)

Animal models that allow concurrent access to drug and nondrug reinforcers provide unique insight into the etiology, maintenance, and treatment of drug use.We sought to develop and utilize a concurren...

Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.

Neuropharmacology 99 , 142-55, (2015)

Chronic treatment with nicotine is known to increase the α4β2-nAChR sites in brain, to decrease α6β2-nAChR sites and to have minimal effect on α3β4-and α7-nAChR populations. Varenicline is now used as...

Effects of varenicline on ethanol-induced conditioned place preference, locomotor stimulation, and sensitization.

Alcohol. Clin. Exp. Res. 38(12) , 3033-42, (2015)

Varenicline, a partial nicotinic acetylcholine receptor (nAChR) agonist, is a promising new drug for the treatment of alcohol (ethanol [EtOH]) dependence. Varenicline has been approved by the Food and...


More Articles


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.